PMH6 MENTAL HEALTH IN THE FIRST MONTHS OF HEMODIALYSIS AS A PREDICTOR OF SURVIVAL
Valdés C 1 , García Mendoza M 1 , Rebollo P 2 , Ortega F 1 1 Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, 2 BAP Health Outcomes, Oviedo, Asturias, Spain OBJECTIVES: The aim of this study was to evaluate the survival of patients initiating hemodialysis (HD), and to analyze whether low Health-Related Quality of Life (HRQoL) levels are predictors of mortality in the short term, controlling certain variables that had been shown in other studies to have a bearing on survival, and using scores, standardized for age and sex, of the HRQoL measurement tool employed. METHODS: A multicentric prospective study of all patients on HD in all the dialysis units in Asturias, a region with a little over one million inhabitants, from the 1st of January 2001 to the 30th September 2002. A total of 199 patients initiated HD in our region and survived the first 3 months. A total of 137 patients who remained in HD for at least three months had complete responses on HRQoL measures, those that had received a transplant during the followup were censored to survival analysis. RESULTS: It was observed adjusted relative risk (RR) of death increased by 5% for each year age increased; RR = 1.05 (CI 95% 1.01 1.09): p = 0.006, in the same way that for each point that MCS increased, the adjusted RR of death diminished 4%; RR = 0.96 (CI 95% 0.94 0.99); p = 0.006. CONCLUSIONS: Mental health has been shown to be a factor independently associated with mortality; as the MCS score worsens the adjusted relative risk of death of a patient in HD increases.
PMH7

OFF-LABEL UTILIZATION OF METHYLPHENIDATE FOR ADULTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD) IN GERMANY: INSIGHTS FROM THE NORDBADEN PROJECT
Schlander M 1 , Schwarz O 1 ,Viapiano M 2 , Bonauer N 2 1 Institute for Innovation & Valuation in Health Care (InnoVal-HC), Eschborn, Germany, 2 Kassenaerztliche Vereinigung Baden-Wuerttemberg, Karlsruhe, Germany In routine clinical care, ADHD is rarely diagnosed in the adult population in Germany. Little is known about actual care for adult outpatients. To date, no pharmaceutical product has been licensed in Germany for use in adult ADHD. OBJECTIVE: To assess the (off-label) use of methylphenidate in this group of patients, using the comprehensive medical claims database of Nordbaden/Germany, covering an insured population of 2.234 m (or 2.7% of the German population), and hereof 1.766 m adults, in 2003. METHODS: 630 adults with a diagnosis of ADHD (ICD-10-codes F90.0, F90.1, "Hyperkinetic Disorder") were identified (administrative prevalence: 0.04%). For a retrospective analysis of methylphenidate prescriptions by gender and coexisting conduct disorder, data from the organization of licensed physicians (Kassenaerztliche Vereinigung) in Nordbaden/Germany were combined with data from the regional vdak, an association of statutory sick funds. RESULTS: One third (34.6%) of adult patients with ADHD were treated (offlabel) with methylphenidate. Treatment prevalence was somewhat higher for males (39.4%, 95%-CI 31.3%-48.0%; cf. females, 29.0%, 21.2%-37.9%). Patients with pure Hyperkinetic Disorder (F90.0) appeared to be more likely (36.8%, 30.7%-43.3%) than patients with concomitant conduct disorder (F90.1: 14.8%, 4.2%-33.7%) to receive medication (methylphenidate). Most methylphenidate prescriptions for adult patients were written by psychiatrists and other mental health care specialists (50% of DDDs) and by general practitioners (31%). Adult patients accounted for 9% of the total number of methylphenidate prescriptions for patients with ADHD in Nordbaden. CONCLUSIONS: Besides the low administrative prevalence of adult ADHD in Nordbaden, the relatively higher medication rate of patients without concomitant conduct disorder constitutes a peculiar difference compared to prescribing patterns observed for children and adolescents. Though currently the budgetary impact of adult ADHD seems moderate, this is likely to change when physicians begin to recognize adult ADHD more frequently, and once drugs for treatment of the condition will have been licensed.
PMH8 BUDGET IMPACT MODEL FOR DETERMINING THE COSTS OF INTRODUCING ZIPRASIDONE FOR THE MANAGEMENT OF ACUTE BIPOLAR MANIA IN SPAIN
Darba J 1 , Restovic G 1 , Rejas J 2 1 Universitat de Barcelona, Barcelona, Spain, 2 Pfizer Spain, Alcobendas, Madrid, Spain OBJECTIVES: A budget impact model was used to estimate the effect of introducing ziprasidone on acute bipolar mania drugrelated costs in Spain. METHODS: The model is based on disease prevalence, incidence, drug use, adverse effects, drug acquisition cost and sales forecasting data specific to Spain. It takes the perspective of the Spanish National Pharmaceutical budget and has a time horizon of 3 years. Drugs considered in the study were lithium, valproate, olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, lamotrigine, oxcarbazepine and topiromate. Market shares for ziprasidone for the upcoming three years were estimated at 9%, 14% and 17%. RESULTS:
